{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"The study was terminated early due to futility as determined by Amgen's Carfilzomib NASCR program in addition to low enrollment."},"pointOfContact":{"email":"vanrheefrits@uams.edu","organization":"University of Arkansas for Medical Sciences","phone":"501-526-2873","title":"Frits Van Rhee, MD"}}